Business Description
Mayne Pharma Group Ltd
NAICS : 325412
SIC : 2834
ISIN : AU000000MYX0
Description
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.23 | |||||
| Equity-to-Asset | 0.48 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.44 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.57 | |||||
| Beneish M-Score | -1.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -28.4 | |||||
| 3-Year EBITDA Growth Rate | -101.6 | |||||
| 3-Year EPS without NRI Growth Rate | -139.2 | |||||
| 3-Year Book Growth Rate | -14.9 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.88 | |||||
| 9-Day RSI | 59.24 | |||||
| 14-Day RSI | 57.68 | |||||
| 6-1 Month Momentum % | 91.21 | |||||
| 12-1 Month Momentum % | 74.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.61 | |||||
| Quick Ratio | 1.3 | |||||
| Cash Ratio | 0.52 | |||||
| Days Inventory | 410.15 | |||||
| Days Sales Outstanding | 279.69 | |||||
| Days Payable | 682.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | 38.18 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 66.92 | |||||
| Operating Margin % | -37.04 | |||||
| Net Margin % | -90.47 | |||||
| FCF Margin % | -12.67 | |||||
| ROE % | -36.86 | |||||
| ROA % | -18.75 | |||||
| ROIC % | -16.53 | |||||
| ROC (Joel Greenblatt) % | -157.34 | |||||
| ROCE % | -16.18 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 5.24 | |||||
| PS Ratio | 2.16 | |||||
| PB Ratio | 1.06 | |||||
| EV-to-EBIT | -3.14 | |||||
| EV-to-Forward-EBIT | -11.81 | |||||
| EV-to-EBITDA | -5.87 | |||||
| EV-to-Forward-EBITDA | 4.57 | |||||
| EV-to-Revenue | 1.81 | |||||
| EV-to-Forward-Revenue | 1.15 | |||||
| EV-to-FCF | -13.16 | |||||
| Price-to-Median-PS-Value | 1.71 | |||||
| Earnings Yield (Greenblatt) % | -31.82 | |||||
| FCF Yield % | -5.62 | |||||
| Forward Rate of Return (Yacktman) % | -22.32 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers